BR0208283A - Uso de escitaloprama, e, composição farmacêutica - Google Patents
Uso de escitaloprama, e, composição farmacêuticaInfo
- Publication number
- BR0208283A BR0208283A BR0208283-7A BR0208283A BR0208283A BR 0208283 A BR0208283 A BR 0208283A BR 0208283 A BR0208283 A BR 0208283A BR 0208283 A BR0208283 A BR 0208283A
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- disorders
- escitaloprama
- treatment
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
"USO DE ESCITALOPRAMA, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se ao uso de escitaloprama pura enanciomérica e/ou de medicamentos de baixa dose do mesmo para o tratamento aperfeiçoado de depressão, em particular de distúrbio de depressão maior, distúrbios neuróticos, e distúrbio de estresse agudo, distúrbios alimentares, tais como bulimia, anorexia e obesidade, fobias, distimia, e síndrome pré-menstrual, distúrbios cognitivos, distúrbios de controle de impulso, distúrbio de hiperatividade de déficit de atenção ou abuso de droga. Os medicamentos podem estar também incluídos no tratamento de distúrbio de atenção maior em pacientes "resistentes a tratamento".
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200100684 | 2001-05-01 | ||
PCT/DK2002/000281 WO2002087566A1 (en) | 2001-05-01 | 2002-05-01 | The use of enantiomeric pure escitalopram |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0208283A true BR0208283A (pt) | 2004-03-09 |
Family
ID=8160464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0208283-7A BR0208283A (pt) | 2001-05-01 | 2002-05-01 | Uso de escitaloprama, e, composição farmacêutica |
Country Status (25)
Country | Link |
---|---|
US (7) | US20040198809A1 (pt) |
EP (1) | EP1385503A1 (pt) |
JP (1) | JP2004527551A (pt) |
KR (2) | KR20100012089A (pt) |
CN (1) | CN1509169A (pt) |
AR (1) | AR033308A1 (pt) |
AT (1) | AT10974U1 (pt) |
BG (1) | BG108379A (pt) |
BR (1) | BR0208283A (pt) |
CA (1) | CA2445843A1 (pt) |
CZ (1) | CZ20033267A3 (pt) |
EA (1) | EA200301195A1 (pt) |
HR (1) | HRP20030744A2 (pt) |
HU (1) | HUP0400054A3 (pt) |
IL (1) | IL158031A0 (pt) |
IS (1) | IS6954A (pt) |
ME (1) | MEP5908A (pt) |
MX (1) | MXPA03008777A (pt) |
NO (1) | NO20034538D0 (pt) |
PL (1) | PL367480A1 (pt) |
SK (1) | SK14612003A3 (pt) |
UA (1) | UA82828C2 (pt) |
WO (1) | WO2002087566A1 (pt) |
YU (1) | YU85303A (pt) |
ZA (1) | ZA200307102B (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
IL158031A0 (en) * | 2001-05-01 | 2004-03-28 | Lundbeck & Co As H | The use of enantiomeric pure escitalopram |
NZ540281A (en) * | 2002-12-23 | 2008-07-31 | Lundbeck & Co As H | Escitalopram hydrobromide and a method for the preparation thereof |
US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
EP1691811B1 (en) * | 2003-12-11 | 2014-07-23 | Sunovion Pharmaceuticals Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
US20050196453A1 (en) | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
CA2558198A1 (en) * | 2004-03-05 | 2005-09-15 | H. Lundbeck A/S | Crystalline composition containing escitalopram oxalate |
TWI347942B (en) * | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
EA200801080A1 (ru) * | 2005-10-14 | 2009-02-27 | Х. Лундбекк А/С | Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион |
CA2625835A1 (en) | 2005-10-14 | 2007-05-10 | Forest Laboratories, Inc. | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
CN100353939C (zh) * | 2006-01-05 | 2007-12-12 | 昆明积大制药有限公司 | 含西酞普兰和环糊精的抗抑郁口服药用组合物 |
US20070259952A1 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Uses of escitalopram |
TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
US8252336B2 (en) * | 2006-10-20 | 2012-08-28 | Ratiopharm Gmbh | Escitalopram and solid pharmaceutical composition comprising the same |
US20100003313A1 (en) * | 2006-10-27 | 2010-01-07 | Hisamitsu Pharmaceutical Co.,Inc. | Adhesive skin patch |
EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
DK2185155T3 (en) * | 2007-08-03 | 2018-01-02 | Richter Gedeon Nyrt | PHARMACEUTICAL COMPOSITIONS WITH DOPAMINE RECEPTOR LIGANDS AND TREATMENT METHODS USING DOPAMINE RECEPTOR LIGANDS |
EP2248808B1 (en) * | 2008-01-31 | 2014-07-16 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
ITMI20080768A1 (it) * | 2008-04-24 | 2009-10-25 | Abiogen Pharma Spa | Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one |
JP5740300B2 (ja) * | 2009-02-27 | 2015-06-24 | 久光製薬株式会社 | 経皮投与製剤 |
US20180071269A1 (en) | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
CA2982898C (en) * | 2015-05-13 | 2023-08-29 | A. Carlsson Research Ab | Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1143702A (pt) * | 1965-03-18 | |||
US4079135A (en) * | 1973-12-13 | 1978-03-14 | Imperial Chemical Industries Limited | Morpholine derivatives as antidepressants |
GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8607313D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
US5958429A (en) * | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
US6069177A (en) * | 1997-07-08 | 2000-05-30 | The Hong Kong University Of Science And Technology | 3-Hydroxy-propanamine derived neuronal reuptake inhibitors |
SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
CZ292911B6 (cs) * | 1997-11-11 | 2004-01-14 | H. Lundbeck A/S | Způsob výroby citalopramu |
AU4850199A (en) * | 1998-06-30 | 2000-01-17 | Eli Lilly And Company | Pyrrolidine and pyrroline derivatives having effects on serotonin related systems |
US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
PL199423B1 (pl) * | 1998-10-20 | 2008-09-30 | Lundbeck & Co As H | Sposób wytwarzania citalopramu |
ATE237604T1 (de) * | 1999-04-14 | 2003-05-15 | Lundbeck & Co As H | Verfahren zur herstellung von citalopram |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
CA2405025A1 (en) * | 2000-04-24 | 2001-11-01 | Aryx Therapeutics | (2-aminoethyl) oxime derivatives for the treatment of depression |
IL158031A0 (en) * | 2001-05-01 | 2004-03-28 | Lundbeck & Co As H | The use of enantiomeric pure escitalopram |
-
2002
- 2002-05-01 IL IL15803102A patent/IL158031A0/xx unknown
- 2002-05-01 HU HU0400054A patent/HUP0400054A3/hu unknown
- 2002-05-01 YU YU85303A patent/YU85303A/sh unknown
- 2002-05-01 ME MEP-59/08A patent/MEP5908A/xx unknown
- 2002-05-01 EP EP02724141A patent/EP1385503A1/en not_active Withdrawn
- 2002-05-01 PL PL02367480A patent/PL367480A1/xx not_active Application Discontinuation
- 2002-05-01 MX MXPA03008777A patent/MXPA03008777A/es unknown
- 2002-05-01 US US10/468,685 patent/US20040198809A1/en not_active Abandoned
- 2002-05-01 CN CNA028092309A patent/CN1509169A/zh active Pending
- 2002-05-01 SK SK1461-2003A patent/SK14612003A3/sk not_active Application Discontinuation
- 2002-05-01 EA EA200301195A patent/EA200301195A1/ru unknown
- 2002-05-01 UA UA2003098415A patent/UA82828C2/xx unknown
- 2002-05-01 KR KR1020097027003A patent/KR20100012089A/ko not_active Application Discontinuation
- 2002-05-01 BR BR0208283-7A patent/BR0208283A/pt not_active IP Right Cessation
- 2002-05-01 CZ CZ20033267A patent/CZ20033267A3/cs unknown
- 2002-05-01 WO PCT/DK2002/000281 patent/WO2002087566A1/en active Application Filing
- 2002-05-01 CA CA002445843A patent/CA2445843A1/en not_active Abandoned
- 2002-05-01 KR KR10-2003-7014286A patent/KR20040030609A/ko active Application Filing
- 2002-05-01 JP JP2002584912A patent/JP2004527551A/ja active Pending
- 2002-05-02 AR ARP020101612A patent/AR033308A1/es unknown
-
2003
- 2003-08-20 US US10/644,587 patent/US20040198811A1/en not_active Abandoned
- 2003-08-20 US US10/644,588 patent/US20040192766A1/en not_active Abandoned
- 2003-08-20 US US10/644,577 patent/US20040198810A1/en not_active Abandoned
- 2003-08-20 US US10/644,576 patent/US20040192764A1/en not_active Abandoned
- 2003-08-20 US US10/644,579 patent/US20040192765A1/en not_active Abandoned
- 2003-09-11 ZA ZA200307102A patent/ZA200307102B/xx unknown
- 2003-09-15 IS IS6954A patent/IS6954A/is unknown
- 2003-09-16 HR HR20030744A patent/HRP20030744A2/xx not_active Application Discontinuation
- 2003-10-09 NO NO20034538A patent/NO20034538D0/no not_active Application Discontinuation
- 2003-11-24 BG BG108379A patent/BG108379A/bg unknown
-
2007
- 2007-09-12 US US11/853,949 patent/US20080004338A1/en not_active Abandoned
-
2008
- 2008-03-21 AT AT0017508U patent/AT10974U1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL158031A0 (en) | 2004-03-28 |
HUP0400054A3 (en) | 2007-03-28 |
EA200301195A1 (ru) | 2004-04-29 |
US20040198809A1 (en) | 2004-10-07 |
NO20034538L (no) | 2003-10-09 |
HRP20030744A2 (en) | 2005-06-30 |
US20040198810A1 (en) | 2004-10-07 |
SK14612003A3 (sk) | 2004-04-06 |
AR033308A1 (es) | 2003-12-10 |
US20040198811A1 (en) | 2004-10-07 |
YU85303A (sh) | 2006-05-25 |
ZA200307102B (en) | 2004-09-13 |
KR20040030609A (ko) | 2004-04-09 |
JP2004527551A (ja) | 2004-09-09 |
EP1385503A1 (en) | 2004-02-04 |
BG108379A (bg) | 2004-11-30 |
NO20034538D0 (no) | 2003-10-09 |
US20080004338A1 (en) | 2008-01-03 |
KR20100012089A (ko) | 2010-02-05 |
CA2445843A1 (en) | 2002-11-07 |
US20040192765A1 (en) | 2004-09-30 |
MEP5908A (xx) | 2010-02-10 |
CZ20033267A3 (en) | 2004-06-16 |
US20040192766A1 (en) | 2004-09-30 |
AT10974U1 (de) | 2010-02-15 |
CN1509169A (zh) | 2004-06-30 |
UA82828C2 (en) | 2008-05-26 |
IS6954A (is) | 2003-09-15 |
PL367480A1 (en) | 2005-02-21 |
US20040192764A1 (en) | 2004-09-30 |
MXPA03008777A (es) | 2004-02-12 |
WO2002087566A1 (en) | 2002-11-07 |
HUP0400054A2 (hu) | 2004-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0208283A (pt) | Uso de escitaloprama, e, composição farmacêutica | |
Tan et al. | Monoamine oxidase-B inhibitors for the treatment of Parkinson’s disease: past, present, and future | |
HUP9801283A2 (hu) | Tomoxetin alkalmazása figyelemhiány/hiperaktivitás betegség kezelésére alkalmas gyógyszerkészítmény előállítására | |
ATE227986T1 (de) | Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 | |
BRPI0210941B8 (pt) | produto farmacêutico contendo combinações de oxazolidinonas substituídas, seu uso, seu processo de produção, e medicamento | |
KR960700742A (ko) | 아토피성질환 치료약(atopic disease remedy) | |
BRPI0411906A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos | |
HUP0303130A2 (hu) | A VII-es faktor és a VIII-as faktor polipeptidek kombinált alkalmazása és ezeket tartalmazó gyógyszerkészítmények | |
NO20030337L (no) | Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber | |
NO20100335L (no) | Behandling av nevrotiske forstyrrelser | |
DE60318237D1 (de) | Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol | |
ATE552031T1 (de) | Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz | |
EE200300514A (et) | Ftalasinoonid, nende kasutamine hingamisteede haigusnähte leevendavate ravimite valmistamiseks ningneid sisaldavad ravimid | |
BR0315082A (pt) | Preparação sólida | |
ATE546151T1 (de) | Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung | |
JP2006514952A5 (pt) | ||
DE69520430T2 (de) | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon | |
BR0201974A (pt) | Composição farmacêutica para tratamento de alterações do sono | |
NO20061167L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon | |
ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
BRPI0407140A (pt) | Droga terapêutica para vìrus | |
Udyavar et al. | Evaluation of antidepressant activity of ethanolic extract of Mimosa pudica in swiss albino mice | |
CA2490638A1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
HUP0102026A2 (hu) | Optikailag tiszta (-)-norciszaprid alkalmazása apnoé, bulimia és más rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására | |
NO20061705L (no) | Anvendelse av agomelatin for a fremstille medikamenter tiltenkt for behandlingen av bipolare lidelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUI DADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 10A ANUIDADE. |